Accessibility Menu
Lunai Bioworks logo

Lunai Bioworks(NASDAQ) ENOB

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-100%
1 Year-88%
1 Month-26%
N/A
Lunai Bioworks last closing stock price
MetricPriceDate
Last closeUSD 2.222026-08-14
Lunai Bioworks stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.88%USD 2.412026-08-07
1 month-25.5%USD 2.982026-07-15
3 month+7.89%USD 2.062026-05-15
Year to date-68.53%USD 7.052025-12-31
1 year-88.34%USD 19.042025-08-14
3 year-98.06%USD 114.402023-08-15
5 year-99.55%USD 488.802021-08-13
Since inception-99.59%USD 548.002018-02-20

Lunai Bioworks Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$128.28M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Mar 9, 2023

ENOB News

A researcher studying a sample in a petri dish

Why Enochian BioSciences Was a Winner on Monday

Eric VolkmanJun 21, 2021
Growth - GettyImages-905948482

Here's Why Enochian BioSciences Stock Skyrocketed Today

Joe TenebrusoJun 14, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lunai Bioworks

Enochian Biosciences, Inc. is a pre-clinical biotechnology firm focused on developing innovative treatments for various human diseases, including HIV, hepatitis B, and cancers. The company aims to advance novel pharmaceutical and biological agents through its extensive research and development pipeline.

Products and Services
  • ENOB-HV-01: Autologous therapy targeting HIV cure
  • ENOB-HV-11: Preventative HIV vaccine candidate
  • ENOB-DC-11: Off-the-shelf dendritic cell vaccine for solid tumors
Growth Outlook
  • Strategic collaborations with leading research organizations enhance development capabilities
  • Focus on multiple high-impact therapeutic areas positions the company for future growth
  • Pipeline includes promising candidates that address unmet medical needs
Financial Highlights
  • Recent quarterly net income of -$2.57 million reflects ongoing investment in R&D
  • Trailing twelve months (TTM) revenue of $0 indicates a focus on development rather than sales
  • Cash and cash equivalents increased to $3.16 million, supporting ongoing operations
Enochian Biosciences operates in a dynamic sector with a commitment to addressing significant health challenges. The company's innovative pipeline and strategic partnerships position it well for potential advancements in biotechnology. Despite current financial challenges, the focus on research and development may lead to breakthroughs that could transform treatment options for patients worldwide. Investors may find the company's dedication to innovation and its robust pipeline of products appealing as it navigates the complexities of the biotechnology landscape.
AI Generated • Jul 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

29

CEO

David Weinstein

Website

www.renovarogroup.com

Headquarters

Los Angeles, CA 90067-2012, US

ENOB Financials

Key Financial Metrics (TTM)

Gross Margin

60.85%

Operating Margin

-69208.27%

Net Income Margin

-66490.45%

Return on Equity

892.52%

Return on Capital

N/A

Return on Assets

-1300.98%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$20.94K

Operating Income

-$133.53M

EBITDA

-$115.50M

Operating Cash Flow

-$5.26M

Capital Expenditure

-$29.77B

Free Cash Flow

-$29.78B

Cash & ST Invst.

$3.16M

Total Debt

$1.41M

Lunai Bioworks Performance Analysis

Lunai Bioworks annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 0N/A
20232023-06-30USD 0N/A
20242024-06-30USD 0N/A
20252025-06-30USD 0N/A
Lunai Bioworks sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30N/A
Q12025-09-30N/A
Q22025-12-31N/A
Q32026-03-31N/A
Lunai Bioworks annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -172.76N/A
20232023-06-30USD -56.42-67.3%
20242024-06-30USD -72.5528.6%
20252025-06-30USD -86.2718.9%
Lunai Bioworks sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30-63433.3%
Q12025-09-30117.1%
Q22025-12-31-161.5%
Q32026-03-31-25.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$20.94K

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

22

N/A

Net Income

-$2.57M

-1459.3%

EBITDA

-$1.47M

+64.5%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$3.16M

+241.8%

Total Debt

$1.41M

-79.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$131.32K

-73.6%

Short Term Debt

$1.28M

-80.4%

Return on Assets

-13.01%

N/A

Return on Invested Capital

14.17%

N/A

Free Cash Flow

-$1.03M

-100.0%

Operating Cash Flow

-$1.03M

+31.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GRNAGreenLight Biosciences Holdings
$0.30-0.03%
RNTXRein Therapeutics Inc.
$0.81+2.35%
BLUEbluebird bio, Inc.
$4.97+0.00%
SYRESpyre Therapeutics, Inc.
$103.63+1.75%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About ENOB

What is the current price of Lunai Bioworks?

Lunai Bioworks is trading at N/A per share.

What is the 52-week range for Lunai Bioworks?

Over the past 52 weeks, Lunai Bioworks has traded between N/A and N/A.

How much debt does Lunai Bioworks have?

As of the most recent reporting period, Lunai Bioworks reported total debt of $1.41M.

How much cash does Lunai Bioworks have on hand?

Lunai Bioworks reported $3.16M in cash and cash equivalents in its most recent financial results.

What is Lunai Bioworks’s dividend yield?

Lunai Bioworks does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services